Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 01, 2021 16:01 ET | Source: Viela Bio

Viela Bio Reports Fourth Quarter and Full Year 2020 Operating and Financial Results

GAITHERSBURG, Md., March 01, 2021 (GLOBE NEWSWIRE) -- Viela Bio (Nasdaq:VIE), a biotechnology company dedicated to the discovery, development and commercialization of novel treatments for patients...
February 25, 2021 08:30 ET | Source: Viela Bio

Viela Bio Announces Additional Positive Results with UPLIZNA® (inebilizumab-cdon) in Patients with Neuromyelitis Optica Spectrum Disorder at the ACTRIMS 2021 Forum

-No new safety signals were identified with prolonged inebilizumab treatment and inebilizumab-mediated B-cell depletion- -UPLIZNA was shown to be safe and effective in patients with previous exposure...
February 22, 2021 07:00 ET | Source: Viela Bio

Viela Bio to Report Fourth Quarter and Full Year 2020 Operating and Financial Results on March 1, 2021

GAITHERSBURG, Md., Feb. 22, 2021 (GLOBE NEWSWIRE) -- Viela Bio (Nasdaq:VIE), a biotechnology company dedicated to the discovery, development and commercialization of novel treatments for patients...
November 10, 2020 16:15 ET | Source: Viela Bio

Viela Bio Reports Third Quarter 2020 Financial Results and Program Highlights

GAITHERSBURG, Md., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Viela Bio (Nasdaq:VIE), a biotechnology company dedicated to the discovery, development and commercialization of novel treatments for autoimmune...
November 05, 2020 16:01 ET | Source: Viela Bio

Viela Bio Announces Final Results from Phase 1b Trial of VIB7734 in Patients with Cutaneous Lupus Erythematosus

-- VIB7734 potently depleted blood and tissue resident plasmacytoid dendritic cells, an important source of inflammatory mediators in autoimmune diseases -- -- Treatment with VIB7734 resulted in...
November 02, 2020 07:00 ET | Source: Viela Bio

Viela Bio to Webcast Third Quarter 2020 Financial Results and Program Highlights on November 10, 2020

GAITHERSBURG, Md., Nov. 02, 2020 (GLOBE NEWSWIRE) -- Viela Bio (Nasdaq:VIE), a biotechnology company dedicated to the discovery, development and commercialization of novel treatments for autoimmune...
September 03, 2020 16:01 ET | Source: Viela Bio

Viela Bio Announces Data Presentations at the 8th Joint ACTRIMS-ECTRIMS Meeting, MS Virtual 2020

GAITHERSBURG, Md., Sept. 03, 2020 (GLOBE NEWSWIRE) -- Viela Bio (Nasdaq:VIE), a biotechnology company dedicated to the discovery, development and commercialization of novel treatments for autoimmune...
August 12, 2020 16:15 ET | Source: Viela Bio

Viela Bio Reports Second Quarter 2020 Financial Results and Program Highlights

GAITHERSBURG, Md., Aug. 12, 2020 (GLOBE NEWSWIRE) -- Viela Bio (Nasdaq:VIE), a biotechnology company dedicated to the discovery, development and commercialization of novel treatments for autoimmune...
August 05, 2020 07:00 ET | Source: Viela Bio

Viela Bio to Webcast Second Quarter 2020 Financial Results and Program Highlights on August 12, 2020

GAITHERSBURG, Md., Aug. 05, 2020 (GLOBE NEWSWIRE) -- Viela Bio (Nasdaq:VIE), a biotechnology company dedicated to the discovery, development and commercialization of novel treatments for autoimmune...
June 11, 2020 17:45 ET | Source: Viela Bio

Viela Bio Announces U.S. FDA Approval of UPLIZNA™ (inebilizumab-cdon) for the Treatment of Neuromyelitis Optica Spectrum Disorder (NMOSD)

GAITHERSBURG, Md., June 11, 2020 (GLOBE NEWSWIRE) -- Viela Bio (Nasdaq:VIE) today announced that the U.S. Food and Drug Administration (FDA) has approved UPLIZNATM (inebilizumab-cdon) for the...